1-2 of 2
Peter W. McLaughlin, MD
Close
Sort by
Journal Articles

Efficacy and Safety of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL).

Issa F. Khouri, MD, Rima M. Saliba, PHD, Chitra Hosing, MD, Rosamar Valverde, RN, William D. Erwin, MS, Luis Fayad, MD, Farzaneh Maadani, BS, Martin J. Korbling, MD, Grace-Julia Okoroji, MS, Anne M. Stachowiak, BS, Barry I. Samuels, MD, Paolo Anderlini, MD, Daniel R. Couriel, MD, Marcos de Lima, MD, Sergio Giralt, MD, Uday Popat, MD, Partow Kebriaei, MD, Naoto T. Ueno, MD, Muzaffar H. Qazilbash, MD, Peter W. McLaughlin, MD, Fredrick B. Hagemeister, MD, Anas Younes, MD, Donald A. Podoloff, MD, Richard E. Champlin, MD
Journal: Blood
Blood (2006) 108 (11): 315.
https://doi.org/10.1182/blood.V108.11.315.315
Published: 2006
Journal Articles

Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL).

Issa F. Khouri, MD, Rima M. Saliba, PhD, Chitra M. Hosing, MD, Sandra A. Acholonu, MPH, Luis E. Fayad, MD, Martin J. Korbling, MD, Celina Saenz, BS, Barbara Pro, MD, Barry I. Samuels, MD, Marcos J. de Lima, MD, Sergio A. Giralt, MD, Anas Younes, MD, Peter W. McLaughlin, MD, Richard E. Champlin, MD
Journal: Blood
Blood (2005) 106 (11): 48.
https://doi.org/10.1182/blood.V106.11.48.48
Published: 2005